Today’s G6PD deficiency diagnosis primarily uses the enzyme activity detection assay, and the main diagnosis used to avoid oxidative hemolysis cannot be other than a phenotypic test, especially in women; however, there is an added value in G6PD genotyping, different sorts of mutations can result in various classes of variations and exhibit various symptoms (Beutler et al., 2002; WHO, 2022). This evidence concerns the gene G6PD and G6PD deficiency.